These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 37112731)
1. Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. Heshin-Bekenstein M; Ziv A; Toplak N; Lazauskas S; Kadishevich D; Ben-Nun Yaari E; Miller-Barmak A; Butbul Aviel Y; Saiag E; Pel S; Elkayam O; Uziel Y; Furer V Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112731 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study. Furer V; Eviatar T; Freund T; Peleg H; Paran D; Levartovsky D; Kaufman I; Broyde A; Elalouf O; Polachek A; Feld J; Haddad A; Gazitt T; Elias M; Higazi N; Kharouf F; Gertel S; Pel S; Nevo S; Hagin D; Zisman D; Elkayam O Ann Rheum Dis; 2022 Nov; 81(11):1594-1602. PubMed ID: 35868846 [TBL] [Abstract][Full Text] [Related]
4. Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study. Eviatar T; Ziv A; Oved A; Miller-Barmak A; Pappo A; Livny R; Amarilyo G; Aviel YB; Naor R; Pel S; Furer V; Elkayam O; Uziel Y; Heshin-Bekenstein M Vaccine; 2024 Dec; 42(26):126426. PubMed ID: 39423454 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases. Ziv A; Heshin-Bekenstein M; Haviv R; Kivity S; Netzer D; Yaron S; Schur Y; Egert T; Egert Y; Sela Y; Hashkes PJ; Uziel Y Rheumatology (Oxford); 2023 Feb; 62(SI2):SI145-SI151. PubMed ID: 35920789 [TBL] [Abstract][Full Text] [Related]
6. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease. Haberman RH; Herati RS; Simon D; Samanovic M; Blank RB; Tuen M; Koralov SB; Atreya R; Tascilar K; Allen JR; Castillo R; Cornelius AR; Rackoff P; Solomon G; Adhikari S; Azar N; Rosenthal P; Izmirly P; Samuels J; Golden B; Reddy S; Neurath M; Abramson SB; Schett G; Mulligan MJ; Scher JU medRxiv; 2021 May; ():. PubMed ID: 34013285 [TBL] [Abstract][Full Text] [Related]
7. Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. Akgün Ö; Çakmak F; Guliyeva V; Demirkan FG; Tanatar A; Hançerli Torun S; Çin D; Meşe S; Ağaçfidan A; Aktay Ayaz N Rheumatology (Oxford); 2022 Nov; 61(11):4482-4490. PubMed ID: 35353139 [TBL] [Abstract][Full Text] [Related]
8. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668 [TBL] [Abstract][Full Text] [Related]
10. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Raptis CE; Berger CT; Ciurea A; Andrey DO; Polysopoulos C; Lescuyer P; Maletic T; Riek M; Scherer A; von Loga I; Safford J; Lauper K; Möller B; Vuilleumier N; Finckh A; Rubbert-Roth A Front Immunol; 2022; 13():1016927. PubMed ID: 36311791 [TBL] [Abstract][Full Text] [Related]
11. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Furer V; Zisman D; Kibari A; Rimar D; Paran Y; Elkayam O Rheumatology (Oxford); 2021 Oct; 60(SI):SI90-SI95. PubMed ID: 33848321 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines. Batıbay S; Ulucaköy RK; Günendi Z; Fidan I; Bozdayı G; Göğüş FN Inflammopharmacology; 2022 Dec; 30(6):2089-2096. PubMed ID: 36282425 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875 [TBL] [Abstract][Full Text] [Related]
15. Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance. Chinnadurai R; Wu HHL; Cox E; Moore J; Clough T; Lamerton E; Donne R; O'Riordan E; Poulikakos D Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455248 [TBL] [Abstract][Full Text] [Related]
16. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Aikawa NE; Kupa LVK; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Rojo PT; Pereira RMR; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Halpern ASR; Fuller R; Souza FHC; Guedes LKN; Assad APL; Moraes JCB; Lopes MRU; Martins VAO; Betancourt L; Ribeiro CT; Sales LP; Bertoglio IM; Bonoldi VLN; Mello RLP; Balbi GGM; Sartori AMC; Antonangelo L; Silva CA; Bonfa E Ann Rheum Dis; 2022 Jul; 81(7):1036-1043. PubMed ID: 35277389 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics. Graceffa D; Sperati F; Bonifati C; Spoletini G; Lora V; Pimpinelli F; Pontone M; Pellini R; Di Bella O; Morrone A; Cristaudo A Front Med (Lausanne); 2022; 9():961904. PubMed ID: 36148445 [TBL] [Abstract][Full Text] [Related]
18. Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study. Sugihara K; Wakiya R; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Ushio Y; Mizusaki M; Mino R; Chujo K; Nomura Y; Inoo M; Kadowaki N; Dobashi H Medicine (Baltimore); 2022 Oct; 101(42):e31288. PubMed ID: 36281134 [TBL] [Abstract][Full Text] [Related]